Suppr超能文献

体重减轻药物治疗:当前和未来的治疗方法。

Weight Loss Pharmacotherapy: Current and Future Therapies.

机构信息

Department of Medicine, Margaret Corbin Campus of the VA New York Harbor Health Care System, New York, NY, USA; Laboratory of Translational Obesity Research, NYU Langone Health, New York, NY, USA.

Department of Medicine, Margaret Corbin Campus of the VA New York Harbor Health Care System, New York, NY, USA; Laboratory of Translational Obesity Research, NYU Langone Health, New York, NY, USA; Holman Division of Endocrinology, New York University Langone Health, 423 East 23rd Street, Room 16-048W, New York, NY 10010, USA.

出版信息

Gastrointest Endosc Clin N Am. 2024 Oct;34(4):591-608. doi: 10.1016/j.giec.2024.06.006.

Abstract

The rising prevalence of obesity is of major concern. There are currently 5 Food and Drug Administration-approved medications for the treatment of obesity: orlistat, phentermine/topiramate, naltrexone/bupropion, liraglutide 3.0 mg, and semaglutide 2.4 mg. Surgical options such as bariatric surgery and endoscopic surgery induce more durable weight loss than pharmacotherapy or lifestyle interventions alone. However, patients often experience weight regain and weight loss plateau after surgery. The addition of multimodal or multihormonal pharmacotherapy is a promising tool to address these challenges. The optimal timing of obesity pharmacotherapy with surgical and endoscopic interventions requires further investigation.

摘要

肥胖症的患病率不断上升,令人尤为担忧。目前有 5 种经美国食品药品监督管理局批准的肥胖症治疗药物:奥利司他、苯丁胺/托吡酯、纳曲酮/安非他酮、利拉鲁肽 3.0mg 和司美格鲁肽 2.4mg。与单独药物治疗或生活方式干预相比,减重手术和内镜手术等手术选择可诱导更持久的体重减轻。然而,患者在手术后常常会经历体重反弹和体重减轻平台期。多模式或多激素药物治疗的联合应用是解决这些挑战的一种有前途的手段。肥胖症药物治疗与手术和内镜干预的最佳时机仍需要进一步研究。

相似文献

1
Weight Loss Pharmacotherapy: Current and Future Therapies.体重减轻药物治疗:当前和未来的治疗方法。
Gastrointest Endosc Clin N Am. 2024 Oct;34(4):591-608. doi: 10.1016/j.giec.2024.06.006.
4
Medications for Obesity: A Review.肥胖症药物治疗:综述。
JAMA. 2024 Aug 20;332(7):571-584. doi: 10.1001/jama.2024.10816.
5
Pharmacological treatment of non-responders following bariatric surgery.肥胖症手术后无应答者的药物治疗。
Minerva Endocrinol (Torino). 2024 Jun;49(2):196-204. doi: 10.23736/S2724-6507.21.03311-3. Epub 2021 Apr 1.
7
Long-term effects of weight-reducing drugs in people with hypertension.减肥药物对高血压患者的长期影响。
Cochrane Database Syst Rev. 2021 Jan 17;1(1):CD007654. doi: 10.1002/14651858.CD007654.pub5.
8
Comparison of the Efficacy of Anti-Obesity Medications in Real-World Practice.真实世界实践中抗肥胖药物疗效的比较。
Drug Des Devel Ther. 2024 Mar 18;18:845-858. doi: 10.2147/DDDT.S445415. eCollection 2024.
9
AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity.AGA 临床实践指南:药物干预成人肥胖症。
Gastroenterology. 2022 Nov;163(5):1198-1225. doi: 10.1053/j.gastro.2022.08.045. Epub 2022 Oct 20.

本文引用的文献

4
Endobariatrics: a Still Underutilized Weight Loss Tool.内镜减重术:一种仍未得到充分利用的减肥工具。
Curr Treat Options Gastroenterol. 2023;21(2):172-184. doi: 10.1007/s11938-023-00420-6. Epub 2023 May 6.
5
Adverse Events Related to Tirzepatide.与替尔泊肽相关的不良事件。
J Endocr Soc. 2023 Jan 26;7(4):bvad016. doi: 10.1210/jendso/bvad016. eCollection 2023 Feb 9.
6
Contemporary medical, device, and surgical therapies for obesity in adults.成人肥胖的当代医学、器械及手术治疗方法。
Lancet. 2023 Apr 1;401(10382):1116-1130. doi: 10.1016/S0140-6736(22)02403-5. Epub 2023 Feb 9.
8
Pharmacologic management of weight regain following bariatric surgery.减重手术后体重反弹的药物治疗管理。
Front Endocrinol (Lausanne). 2023 Jan 9;13:1043595. doi: 10.3389/fendo.2022.1043595. eCollection 2022.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验